429 related articles for article (PubMed ID: 17419952)
1. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
Wiman KG
Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
3. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Baptiste N; Friedlander P; Chen X; Prives C
Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
[TBL] [Abstract][Full Text] [Related]
4. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
Müller P; Nenutil R; Vojtĕsek B
Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers.
Jiang GL; Huang S
Cancer Res; 2001 Mar; 61(5):1796-8. PubMed ID: 11280725
[TBL] [Abstract][Full Text] [Related]
6. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.
Newton HB
Expert Rev Anticancer Ther; 2005 Feb; 5(1):177-91. PubMed ID: 15757449
[TBL] [Abstract][Full Text] [Related]
7. Classic and novel roles of p53: prospects for anticancer therapy.
Fuster JJ; Sanz-González SM; Moll UM; Andrés V
Trends Mol Med; 2007 May; 13(5):192-9. PubMed ID: 17383232
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
9. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
10. The dual role of mutant p53 protein in chemosensitivity of human cancers.
Mueller H; Eppenberger U
Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
[TBL] [Abstract][Full Text] [Related]
11. The p53 tumour suppressor gene.
Steele RJ; Thompson AM; Hall PA; Lane DP
Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903
[TBL] [Abstract][Full Text] [Related]
12. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
14. Induction of efficient apoptosis and cell-cycle arrest in tumor cells by adenovirus-mediated p53 A4 mutant.
Maeda A; Nakamura S; Isono M; Osaki M; Ito H; Sato K
Pathol Int; 2006 Mar; 56(3):126-34. PubMed ID: 16497245
[TBL] [Abstract][Full Text] [Related]
15. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
17. [p53 as a molecular target for cancer therapy].
Ishioka C; Osada M; Gamo M; Kanamaru R
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
[TBL] [Abstract][Full Text] [Related]
18. [New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
Wiman KG
Lakartidningen; 1997 Sep; 94(38):3268-72. PubMed ID: 9379794
[TBL] [Abstract][Full Text] [Related]
19. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
Abarzúa P; LoSardo JE; Gubler ML; Neri A
Cancer Res; 1995 Aug; 55(16):3490-4. PubMed ID: 7627952
[TBL] [Abstract][Full Text] [Related]
20. Overview of novel anticancer drug targets.
Buolamwini JK; Assefa H
Methods Mol Med; 2003; 85():3-28. PubMed ID: 12710193
[No Abstract] [Full Text] [Related]
[Next] [New Search]
